Compare Biogen Inc (BIIB) vs ON Holding AG (ONON) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

ONON stock plunged 19.93% to $31.05 after Q2 2026 results, driven by a revenue miss and lowered full-year growth guidance. Despite beating EPS estimates in recent quarters, the company faces wholesale channel softness and cautious consumer spending. Technical indicators are bearish, with the price near key support at $30, while fundamentals show strong profitability margins and positive cash flow trends. Analyst sentiment remains largely bullish with a $52.86 consensus target, but near-term volatility persists.

The outlook is mixed: long-term growth potential exists via direct-to-consumer strength and margin expansion, but investors face risks from guidance uncertainty and competitive pressures. The sharp sell-off may present a buying opportunity for patient investors, though volatility could continue until wholesale trends stabilize.